NorthShore University HealthSystem, Division of Gastroenterology, 2650 Ridge Avenue, Suite G221, Evanston, IL 60201.
NorthShore University HealthSystem, Division of Gastroenterology, 2650 Ridge Avenue, Suite G221, Evanston, IL 60201.
Transl Res. 2021 Apr;230:197-207. doi: 10.1016/j.trsl.2020.11.013. Epub 2020 Dec 2.
Clostridioides difficile infection (CDI) has had a devastating impact worldwide with significant rates of mortality, especially among the elderly. Despite effective antibiotics, the incidence of recurrent CDI (rCDI) is increasing and more difficult to treat with antibiotics alone. Fecal Microbiota Transplantation (FMT) has emerged as a consistently effective treatment for rCDI. Mechanisms for FMT are not entirely understood, but remain an area of active investigation. There have been recent safety reports with the use of FMT regarding transmission of pathogens in a few patients that have led to serious illness. With appropriate screening, FMT can be safely administered and continue to have a significant impact on eradication of rCDI and improve the lives of patients suffering from this disease. In this review, we summarize current treatments for CDI with a focus on microbiota-based therapies used for antibiotic refractory disease.
艰难梭菌感染（CDI）在全球范围内造成了毁灭性的影响，死亡率尤其高，尤其是在老年人中。尽管有有效的抗生素，复发性艰难梭菌感染（rCDI）的发病率仍在上升，单独使用抗生素治疗更加困难。粪便微生物群移植（FMT）已成为 rCDI 的一种有效治疗方法。FMT 的作用机制尚不完全清楚，但仍然是一个活跃的研究领域。最近有关于 FMT 使用的安全性报告，少数患者在使用 FMT 后出现了病原体传播，导致严重疾病。通过适当的筛查，可以安全地进行 FMT，并继续对 rCDI 的根除产生重大影响，改善患有这种疾病的患者的生活。在这篇综述中，我们总结了 CDI 的当前治疗方法，重点是用于抗生素难治性疾病的基于微生物组的治疗方法。
